A phase II study to evaluate the safety and efficacy of the combination of ZD1839 (IRESSA), docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2007
At a glance
- Drugs Cisplatin; Docetaxel; Gefitinib
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 16 Dec 2007 Status changed from in progress to completed.
- 16 Feb 2006 New trial record.